ChemicalBook > CAS DataBase List > Safinamide

Safinamide

Product Name
Safinamide
CAS No.
133865-89-1
Chemical Name
Safinamide
Synonyms
CS-484;FCE 26743;SAFINAMID;Safinamide;EMD 1195686;Salfenamide;Safranamide;Safinamide >Safinamide IMP;Safinamide Crude
CBNumber
CB71011620
Molecular Formula
C17H19FN2O2
Formula Weight
302.34
MOL File
133865-89-1.mol
More
Less

Safinamide Property

Melting point:
208-212°
Boiling point:
476.7±40.0 °C(Predicted)
Density 
1.189±0.06 g/cm3(Predicted)
storage temp. 
under inert gas (nitrogen or Argon) at 2–8 °C
solubility 
Soluble in DMSO (up to 50 mg/ml).
form 
solid
pka
16.03±0.50(Predicted)
color 
White
Merck 
14,8315
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
More
Less

Safety

RTECS 
TX1457385
HS Code 
2924.29.7790
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H319Causes serious eye irritation

Precautionary statements

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

TCI Chemical
Product number
S0935
Product name
Safinamide
Purity
>98.0%(HPLC)
Packaging
25mg
Price
$145
Updated
2024/03/01
TCI Chemical
Product number
S0935
Product name
Safinamide
Purity
>98.0%(HPLC)
Packaging
100mg
Price
$426
Updated
2024/03/01
Chem-Impex
Product number
38260
Product name
Safinamide,≥98%(HPLC)
Purity
≥98%(HPLC)
Packaging
100MG
Price
$464.76
Updated
2021/12/16
AK Scientific
Product number
6135AA
Product name
(S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide
Packaging
100mg
Price
$614
Updated
2021/12/16
Biorbyt Ltd
Product number
orb146172
Product name
Safinamide
Purity
>99%
Packaging
100mg
Price
$615.4
Updated
2021/12/16
More
Less

Safinamide Chemical Properties,Usage,Production

Description

Safinamide (133865-89-1) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A.1?Displays anticonvulsant activity2?and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models3. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade.4?A novel therapeutic for Parkinson’s disease with multiple modes of action.5?Effective as an add-on to dopamine agonist therapy in early Parkinson’s.6

History

Safinamide is an α-aminoamide derivative with a multimodal mechanism of action involving both dopaminergic and non-dopaminergic properties. It increases levels of available dopamine through dopamine reuptake inhibition andMAO-B inhibition. It is a potent and reversible inhibitor of MAO-B, with significantly greater selectivity for MAO-B over MAO-A than selegiline and rasagiline. However, it also has an important and novel mode of action that involves blockade of Na+ channels andmodulation of Ca2+ channels that inhibits glutamate release and therefore may provide a level of cognitive improvement and neuroprotection. Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. In PD, this relationship is altered, resulting in upregulation of cortico-striatal glutamatergic function in l-dopa-induced dyskinesia. Any drug that can counteract such unbalance in glutamate function is potentially useful in controlling dyskinesias.
Safinamide was originated by Farmitalia Carlo Erba, a company that was later purchased by Pharmacia. Newron Pharmaceuticals was established as a spin-off of Pharmacia in 1999 and acquired safinamide rights and intellectual property from Pharmacia Corporation. Newron originally granted Serono exclusive worldwide rights to develop, manufacture, and commercialize safinamide in 2006. However, in October 2011, Merck Serono agreed to return full global rights for safinamide to Newron. Newron then finalized a strategic collaboration and license agreement with Zambon for the worldwide development and commercialization of safinamide.

Indications

In 2003 positive preliminary results from a phase II trial of safinamide in epilepsy were announced. This open-labeled study was initiated to assess tolerability and drug–drug interaction (DDI) of safinamide in 48 patients with uncontrolled seizures that had already been treated with up to three other antiepileptic drugs. Starting with an initial oral dose of 50mg d−1, safinamide was increased every two weeks up to 300 mg d−1 or to the maximum tolerated dose. An interim analysis of the first 29 patients who completed the study showed excellent tolerability. In this group, no DDI was noted at any of the tested doses in that safinamide did not alter the kinetics of the other antiepileptic drugs. In this interim analysis safinamide was shown to be well tolerated in patients with medically intractable seizures. No serious AEs occurred in the study. Even though the study was not designed and powered to provide proof of efficacy, the sponsor reported that preliminary data showed a significant reduction in median seizure frequency from 50mg progressing up to the highest dose.
In 2005 safinamide was administered to a total of 10 patients with RLS that were enrolled into a single-center, phase II open-labeled pilot study. Each patient was administered safinamide (100 mg d−1) at bedtime for 2 weeks. A significant improvement in all efficacy parameters studied was observed when patients received safinamide. RLS is a neurological disorder characterized by jerky movements of the lower extremities that appear mostly in the evening and during sleep. As reported in a press release, safinamide was also found to be well tolerated and did not exhibit any clinically relevant side effects, but no study results have been published.

Definition

ChEBI: Safinamide is an amino acid amide.

Mechanism of action

Safinamide may exert its in vivo effects through different mechanisms of action. It did not display activity against >80 different types of dopamine, glutamate, adenosine, serotonin, muscarinic, nicotinic, and GABA receptors. Conversely, potent modulation of DA metabolism, blockade of Na+/Ca2+ channels, and inhibition of glutamate release have been demonstrated. It has pointed out that the electrophysiological and neurochemical effects of safinamide are apparent at effective anticonvulsant concentrations. For example, pharmacokinetics (PK) showed that brain levels reach roughly 40 μM, at 30 and 60min after an oral dose of 10 mg kg?1 safinamide in rats. These points in time correspond to the peak anticonvulsant effect observed in the MES epilepsy model. This micromolar concentration approximates the concentration of safinamide that gives effective inhibition of excitatory amino acid release and reduction of sustained repetitive firing (SRF). Importantly, safinamide partitions itself well into the brain, where drug levels are approximately 10-fold higher than in plasma.

Clinical Use

Highly selective and reversible MAO-B inhibitor:
Treatment of Parkinson’s disease

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: avoid with pethidine.
Antibacterials: possible enhanced hypotensive effect with linezolid and tedizolid.
Antidepressants: increased risk of hypertension
and CNS excitation with SSRIs and tricyclics - adjust SSRI or tricyclic doses, avoid or adjust dose of fluoxetine and fluvoxamine; possible enhanced hypotensive effect with MAOIs and moclobemide - avoid.
Sympathomimetics: use with caution.

Metabolism

There are three routes of hepatic metabolism. The main route involves hydrolytic oxidation of the amide moiety leading to the main metabolite safinamide acid (NW- 1153). Another pathway involves oxidative cleavage of the ether bond forming 'O-debenzylated safinamide' (NW-1199). Finally the 'N-dealkylated acid' (NW-1689) is formed by oxidative cleavage of the amine bond of either safinamide (minor) or the primary safinamide acid metabolite (NW-1153) (major). The 'N-dealkylated acid' (NW-1689) undergoes conjugation with glucuronic acid yielding its acyl glucuronide. None of these metabolites are pharmacologically active.
In humans, safinamide is almost exclusively eliminated via metabolism of which 76% is renal and 1.5% via the faeces.

References

1) Strolin Benedetti?et al.?(1994),?The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats;?J. Pharm. Pharmacol.,?46?814 2) Fariello?et al.?(1998),?Preclinical evaluation of PNU-151774E as a novel anticonvulsant; J. Pharmacol. Exp. Ther.?285?397 3) Maj?et al.?(1998),?PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat; Eur, J. Pharmacol.,?59?27 4) Gardoni?et al.?(2018),?Safinamide Modulates Striatal glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia; J. Pharmacol. Exp. Ther., 367?442 5) Caccia?et al.?(2006),?Safinamide: from molecular targets to a new anti-Parkinson drug; Neurology,?67(7 Suppl. 2)?S18 6) Schapira?et al.?(2013),?Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease; Eur. J. Neurol.,?20?271

Safinamide Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Safinamide Suppliers

Belgium 1 China 213 France 2 Germany 1 India 21 Italy 1 Japan 1 United Kingdom 3 United States 31 Global 274
Ark Pharm, Inc.
Tel
847-367-3680
Fax
847-367-3681
Email
sales@arkpharminc.com
Country
United States
ProdList
1670
Advantage
56
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Country
United States
ProdList
14055
Advantage
65
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81215950 4000-868-328
Email
customer@uwalab.com
Country
United States
ProdList
10404
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38463
Advantage
58
Aceschem Inc.
Tel
+1-817863-6948 +1-（817）863-6948
Email
sales@aceschem.com
Country
United States
ProdList
19632
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
Alfa Chemistry
Tel
--
Fax
--
Email
info@Alfa-Chemistry.com
Country
United States
ProdList
6814
Advantage
0
APAC Pharmaceutical, LLC
Tel
--
Fax
--
Email
sales@apacpharma.com
Country
United States
ProdList
6322
Advantage
38
Focus Biomolecules
Tel
--
Fax
--
Email
sales@focusbiomolecules.com
Country
United States
ProdList
1284
Advantage
58
Jubilant Pharma Holdings Inc.
Tel
--
Fax
--
Email
bd.api@jubl.com
Country
United States
ProdList
39
Advantage
58
MilliporeSigma (Sigma-Aldrich Corp.)
Tel
--
Fax
--
Email
@sial.com
Country
United States
ProdList
5414
Advantage
58
AbovChem LLC
Tel
--
Fax
--
Email
sales@abovchem.com
Country
United States
ProdList
59
Advantage
58
Aurum Pharmatech, LLC
Tel
--
Fax
--
Email
sales@aurumpharmatech.com
Country
United States
ProdList
498
Advantage
0
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
MedKoo Biosciences, Inc.
Tel
--
Fax
--
Email
sales@medkoo.com
Country
United States
ProdList
126
Advantage
58
eNovation Chemicals LLC
Tel
--
Fax
--
Email
ales@eNovationChem.com
Country
United States
ProdList
1673
Advantage
58
ChemArch LLC
Tel
--
Fax
--
Country
United States
ProdList
15
Advantage
58
OX CHEM
Tel
--
Fax
--
Email
sales@ox-chem.com
Country
United States
ProdList
759
Advantage
50
TCI America, Inc. (part of Tokyo Chemical Industry)
Tel
--
Fax
--
Email
Angelina.Crew@tcichemicals.com
Country
United States
ProdList
2053
Advantage
58
Spectrum Chemicals & Laboratory Products
Tel
--
Fax
--
Email
sales@spectrumchemical.com
Country
United States
ProdList
6699
Advantage
77
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
TCI America
Tel
--
Fax
--
Email
sales@tciamerica.com
Country
United States
ProdList
6909
Advantage
75
More
Less

View Lastest Price from Safinamide manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Safinamide 133865-89-1
Price
US $0.00-0.00/Kg/Drum
Min. Order
1KG
Purity
98%min
Supply Ability
500kgs
Release date
2021-10-18
Zison Pharmaceutical (Shandong) Co., Ltd.
Product
Safinamide ,Safinamide base 133865-89-1
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
＞99% by HPLC
Supply Ability
100kg/month
Release date
2023-01-05
Career Henan Chemical Co
Product
Safinamide 133865-89-1
Price
US $7.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
JD 669
Release date
2019-09-01

133865-89-1, SafinamideRelated Search:

3-(3-fluorobenzyl)-4-(3-fluoro-benzyloxy)benzaldehyde FCE 28073 (S)-2-((4-((4-fluorobenzyl)oxy)benzyl)amino)propanamide (S)-2-((4-(benzyloxy)benzyl)amino)propanamide Safinamide Impurity 9 Safinamide Impurity 5 Tetrabenazine L(+)-Arginine Entacapone tadalafi VILAZODONE Rasagiline Titanium carbide Chromium carbide VIGABATRIN Tenofovir Obeticholic Acid Safinamide mesylate

  • SAFINAMIDE:(S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANSULFONATE
  • FCE 26743
  • Safinamide
  • EMD 1195686;FCE 26743;EMD-1195686;EMD1195686;FCE-26743
  • Safinamide ,Safinamide base
  • Safinamide Intermediate 2
  • (S)-(+)-2-[4-(3-Fluorobenzyloxy)benzylamino]propanamice methansulfonate
  • CS-484
  • FCE-28073(R-isomer)
  • FCE-28073(R-ISOMER); PNU-151774E; NW-1015
  • Safinamide Impurity D
  • 2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide
  • PropanaMide,2-[[[4-[(3-fluorophenyl)Methoxy]phenyl]Methyl]aMino]-, (2S)-
  • (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)aMino)propanaMide
  • (S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANSULFONATE
  • EMD 1195686
  • SAFINAMID
  • Safinamide Impurity
  • (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
  • Safinamide IMP
  • Safinamide, >=98%
  • (4-((3-fluorobenzyl)oxy)benzyl)-L-alanine
  • Safinamide mesylate Intermediate 2
  • Salfenamide
  • Safinamide &gt
  • Safinamide/Safinamide methanesulfonate
  • (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide
  • Safinamide USP/EP/BP
  • Safinamide Impueity
  • SAFINAMIDE:(S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPA...
  • SafinamideQ: What is Safinamide Q: What is the CAS Number of Safinamide Q: What is the storage condition of Safinamide
  • Safinamide (FCE 26743)
  • Safranamide
  • Safinamide Crude
  • 133865-89-1
  • 33865-89-1
  • chemical